USPTO serial 79398160
SANWAY GENE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 21, 2025
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SANWAY GENE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Yue (Robert) Xu
Yue (Robert) Xu Apex Attorneys at Law, LLP160 Alamo Plaza #942Alamo, CA 94507United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; antibiotics; vaccine preparations; pharmaceutical preparations for treating allergies; preparations for detecting genetic predispositions for medical purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; genetic identity tests comprised of reagents for medical purposes; reagent paper for medical purposes; reagents for medical use; biological preparations for medical purposes for the prevention and treatment of disorders of the digestive system, blood system, the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and of the genitourinary system, for the prevention and treatment of infectious diseases, viral diseases, and inflammatory disorders, for use in dermatology, oncology, hematology, tissue and organ transplantation, and ophthalmology and for the treatment of gastroenterological disorders; diagnostic biomarker reagents for medical purposes; immunoassay reagents for medical use; enzyme preparations for medical purposes; reagents for use in medical genetic testing; mineral, vitamin, or nutritionally enhanced water for medical purposes; medicated water for the treatment of illnesses attributed to insufficient cellular energy; medicated water for the treatment of allergies, cough, cold, flu, headache, and pain; medicated water for the treatment of infectious diseases, skin diseases and conditions, and internal tissue diseases and conditions; medicated water for the treatment of pain, nausea and muscle spasms; medicated water-based solutions for treating skin infections and skin conditions; medicated water for the treatment of gastrointestinal disorders; demineralised water for medical purposes; diagnostic kits comprised of medical diagnostic reagents for use in disease testing, health monitoring, and predictive and preventive medicine in the fields of detecting diseases related to cancer, infectious diseases, viral diseases, hereditary diseases, inflammatory disorders, and oncological disorders of the digestive system, blood system, reproductive system, the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; purified biochemical medical diagnostic reagents, namely, protein arrays, enzymes, and fluorescent dyes for use as reagents in medical diagnostic applications; biological preparations for the diagnosis of disorders of the digestive system, blood system, the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system and for the diagnosis of cancer, hereditary diseases, infectious diseases, viral diseases, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; biological preparations for the treatment of disorders of the digestive system, blood system, the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system and for the treatment of cancer, hereditary diseases, infectious diseases, viral diseases, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; biochemical drugs for the diagnosis of disorders of the digestive system, blood system, the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system and for the diagnosis of cancer, infectious diseases, viral diseases, hereditary diseases, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; biochemical drugs for the treatment of disorders of the digestive system, blood system, the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system and for the treatment of cancer, infectious diseases, viral diseases, hereditary diseases, inflammatory disorders, dermatological conditions, oncological diseases, blood diseases, connective tissue disorders, ophthalmic diseases, and gastroenterological disorders; antibiotic tablets; allergy tablets; chemico-pharmaceutical preparations in the nature of biological indicators, in-vivo diagnostic agents, and in-vitro diagnostic reagents all for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, hereditary diseases, viral diseases, and diseases related to the digestive system, blood system, the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; chemical preparations in the nature of biological indicators, in-vivo diagnostic agents, and in-vitro diagnostic reagents all for the diagnosis, monitoring, treatment and prevention of cancer, inflammatory disorders, oncological disorders, infectious diseases, hereditary diseases, viral diseases, and diseases related to the digestive system, blood system, the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, and the genitourinary system; antibiotic ointments; anti-inflammatory ointments; medicated ointments for treating dermatological conditions; ointments for pharmaceutical purposes, namely, anti-itch ointments, hemorrhoidal ointments | ACTIVE | — |
| 010 | Surgical apparatus and instruments; apparatus for use in medical analysis, namely, apparatus for blood analysis, body composition analyzers, apparatus for analyzing and detecting bacteria and viruses, apparatus for analyzing and detecting DNA and RNA, apparatus for analyzing and detecting genes, apparatus for analyzing blood vessels, apparatus for immunoassay analysis, apparatus for organ and tissue cavitation detecting, and apparatus for medical imaging analysis; diagnostic apparatus for medical purposes in the nature of medical diagnostic imaging apparatus, for use with computer displays and computer monitors and for use with recorded computer operating software and recorded smartphone operating software, all sold as a unit; body composition analyzers for medical purposes; apparatus for DNA and RNA testing for medical purposes; analysers for bacterial identification for medical purposes; apparatus used in implementing diagnosis tests designed to detect the abnormal prion protein; genetic testing apparatus for medical purposes; medical equipment, namely, devices for bioanalysis of pathogens in the nature of reagent cartridges for sample preparation, nucleic acid purification, nucleic acid amplification and electrochemical detection all for medical diagnostic purposes; gene testing medical apparatus for identification of genus specific and species specific DNA and RNA sequences; immunochemical testing apparatus for medical use; immunochemical medical diagnostic testing apparatus for detecting and measuring antibody levels; medical diagnostic apparatus for testing for viruses; medical diagnostic apparatus for testing DNA and RNA samples | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Sanway Gene Tech. Inc.
- Other trademarks owned by Sanway Gene Tech. Inc.
- Other trademarks owned by Sanway Gene Tech. Inc.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Similar marks named SANWAY GENE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 5, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 19, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 19, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 29, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 7, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 7, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 22, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 21, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 21, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 3, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 3, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 27, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 5, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 17, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 16, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 16, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 9, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Aug 19, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Aug 17, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 8, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 7, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 1, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 2, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 28, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 20, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |